Imugene have presented the dollar amount of anticipated revenue from Azer cel in Diffuse Large B Cell Lymphoma autogolous CAR T relapsed patients in the US. The number was US$2.6billion per year. That’s just one indication in blood cancers.
How many other blood cancers will we get approved for and what happens when we begin a trial with OnCARlytics for Azer cel to treat solid tumour? The mind boggles at how valuable it is and the many indications it could one day treat once approved.
IMU Price at posting:
2.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)